RU2020105058A3 - - Google Patents

Download PDF

Info

Publication number
RU2020105058A3
RU2020105058A3 RU2020105058A RU2020105058A RU2020105058A3 RU 2020105058 A3 RU2020105058 A3 RU 2020105058A3 RU 2020105058 A RU2020105058 A RU 2020105058A RU 2020105058 A RU2020105058 A RU 2020105058A RU 2020105058 A3 RU2020105058 A3 RU 2020105058A3
Authority
RU
Russia
Application number
RU2020105058A
Other languages
Russian (ru)
Other versions
RU2020105058A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020105058A publication Critical patent/RU2020105058A/ru
Publication of RU2020105058A3 publication Critical patent/RU2020105058A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2020105058A 2017-08-01 2018-07-31 Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она RU2020105058A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539734P 2017-08-01 2017-08-01
US62/539,734 2017-08-01
PCT/US2018/044580 WO2019028008A1 (en) 2017-08-01 2018-07-31 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Publications (2)

Publication Number Publication Date
RU2020105058A RU2020105058A (ru) 2021-09-02
RU2020105058A3 true RU2020105058A3 (enExample) 2021-11-17

Family

ID=65233095

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020105058A RU2020105058A (ru) 2017-08-01 2018-07-31 Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она

Country Status (16)

Country Link
US (2) US11124518B2 (enExample)
EP (1) EP3661918B1 (enExample)
JP (1) JP7203816B2 (enExample)
KR (1) KR20200034781A (enExample)
CN (1) CN111094253B (enExample)
AR (1) AR112774A1 (enExample)
AU (1) AU2018312448B2 (enExample)
BR (1) BR112020002104A2 (enExample)
CA (1) CA3071405A1 (enExample)
ES (1) ES2980537T3 (enExample)
IL (1) IL272262A (enExample)
MX (1) MX2020001235A (enExample)
RU (1) RU2020105058A (enExample)
SG (1) SG11202000789WA (enExample)
TW (1) TW201910335A (enExample)
WO (1) WO2019028008A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
RS66798B1 (sr) * 2018-03-09 2025-06-30 Recurium Ip Holdings Llc Supstituisani 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-oni
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
EP3952876A4 (en) * 2019-04-09 2023-04-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2020210380A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN113939296A (zh) * 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
KR20220042127A (ko) 2019-06-28 2022-04-04 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 피라졸로피리미딘 화합물, 그의 제조 방법 및 그의 응용
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
KR20220103748A (ko) 2019-11-15 2022-07-22 리커리엄 아이피 홀딩스, 엘엘씨 3차 알코올의 키랄 합성
EP4069235A4 (en) * 2019-12-20 2024-01-10 Recurium IP Holdings, LLC ASSOCIATIONS
NZ793883A (en) * 2020-05-15 2025-11-28 Recurium Ip Holdings Llc Mono- and combination therapies
WO2021254389A1 (zh) * 2020-06-17 2021-12-23 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
KR20240004539A (ko) * 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
CN117940430B (zh) * 2021-09-22 2025-10-31 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594425A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
RS58956B1 (sr) * 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP3661918B1 (en) 2024-05-08
WO2019028008A1 (en) 2019-02-07
JP7203816B2 (ja) 2023-01-13
RU2020105058A (ru) 2021-09-02
AU2018312448B2 (en) 2022-09-15
AU2018312448A1 (en) 2020-02-13
ES2980537T3 (es) 2024-10-01
IL272262A (en) 2020-03-31
CA3071405A1 (en) 2019-02-07
TW201910335A (zh) 2019-03-16
MX2020001235A (es) 2020-07-20
AR112774A1 (es) 2019-12-11
EP3661918A1 (en) 2020-06-10
CN111094253A (zh) 2020-05-01
US20210317124A1 (en) 2021-10-14
EP3661918C0 (en) 2024-05-08
CN111094253B (zh) 2023-08-29
US11124518B2 (en) 2021-09-21
SG11202000789WA (en) 2020-02-27
US20200157112A1 (en) 2020-05-21
KR20200034781A (ko) 2020-03-31
BR112020002104A2 (pt) 2020-08-04
EP3661918A4 (en) 2021-05-12
JP2020529993A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
BR122021024397A2 (enExample)
RU2020105058A3 (enExample)
BR202018014992U2 (enExample)
BR122022003518A2 (enExample)
BR202017025154U2 (enExample)
BR202017021228U2 (enExample)
BR202017020981U2 (enExample)
BR202017017068U2 (enExample)
BR202017016984U2 (enExample)
BR202017016924U2 (enExample)
BR202017011220U2 (enExample)
BR202017010814U2 (enExample)
BR202017010373U2 (enExample)
BR202017006953U2 (enExample)
BR202017004898U2 (enExample)
BR202017002937U2 (enExample)
BR202017002826U2 (enExample)
CN304004607S (enExample)
CH714881A1 (enExample)
CN303949240S9 (enExample)
CN303948614S9 (enExample)
CN303943982S8 (enExample)
CN303892651S8 (enExample)
CN303892650S8 (enExample)
CN303993708S (enExample)